Ai‐Ming Yu

8.7k total citations · 3 hit papers
159 papers, 6.8k citations indexed

About

Ai‐Ming Yu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ai‐Ming Yu has authored 159 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Molecular Biology, 53 papers in Cancer Research and 45 papers in Oncology. Recurrent topics in Ai‐Ming Yu's work include MicroRNA in disease regulation (42 papers), RNA Interference and Gene Delivery (36 papers) and RNA modifications and cancer (36 papers). Ai‐Ming Yu is often cited by papers focused on MicroRNA in disease regulation (42 papers), RNA Interference and Gene Delivery (36 papers) and RNA modifications and cancer (36 papers). Ai‐Ming Yu collaborates with scholars based in United States, China and Switzerland. Ai‐Ming Yu's co-authors include Frank J. Gonzalez, Young Hee Choi, Mei‐Juan Tu, Jeffrey R. Idle, Kristopher W. Krausz, Robert L. Haining, A Küpfer, Gavin M. Traber, Pui Yan Ho and Marilyn E. Morris and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Ai‐Ming Yu

150 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

2014 451 citations Young Hee Choi, Ai‐Ming Yu Current Pharmaceutical Design profile →
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

2020 268 citations Ai‐Ming Yu, Young Hee Choi et al. profile →
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

2022 176 citations Gavin M. Traber, Ai‐Ming Yu profile →

Peers

Countries citing papers authored by Ai‐Ming Yu

Since Specialization

Citations

This map shows the geographic impact of Ai‐Ming Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai‐Ming Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai‐Ming Yu more than expected).

Fields of papers citing papers by Ai‐Ming Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ai‐Ming Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai‐Ming Yu. The network helps show where Ai‐Ming Yu may publish in the future.

Co-authorship network of co-authors of Ai‐Ming Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ai‐Ming Yu. A scholar is included among the top collaborators of Ai‐Ming Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ai‐Ming Yu. Ai‐Ming Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Practical Pharmacokinetic–Pharmacodynamic Models in Oncology 2025 ·Pharmaceutics ·(unknown), Mei‐Juan Tu, Ai‐Ming Yu	0
2	Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study 2025 ·International Journal of Surgery ·(unknown), Bufu Tang, Wen Zhang, Yongjie Zhou, (unknown), Ai‐Ming Yu, Changyu Li, Wei Zhang, Zhuoyang Fan, Guowei Yang, (unknown)	0
3	Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors 2025 ·Acta Pharmaceutica Sinica B ·Xiong Zhang, (unknown), (unknown), Yang Yang, Xingling Zheng, Eva Corey, Amina Zoubeidi, Nicholas Mitsiades, Ai‐Ming Yu, (unknown), Hong-Wu Chen	2
4	Immune checkpoint inhibitor‐induced vitiligo: A large‐scale real world pharmacovigilance study 2025 ·International Journal of Cancer ·Bufu Tang, (unknown), (unknown), Ai‐Ming Yu, (unknown), (unknown), Ruiqi Liu, Hanpeng Huang, (unknown), Wenlu Hu, Miaohui Wang, Dandan Guo, Cheng Chi, (unknown)	0
5	Derivation of ecological safety thresholds and risk assessment of new SDHI fungicides in farmland system 2024 ·The Science of The Total Environment ·Jiale Zhang, (unknown), Ronghua Lin, (unknown), (unknown), Nan Zhang, Ai‐Ming Yu	3
6	Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs 2024 ·Frontiers in Pharmacology ·Yimei Wang, Mei‐Juan Tu, Ai‐Ming Yu	7
7	PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells 2024 ·Cancer Research Communications ·(unknown), Shu Ning, (unknown), (unknown), (unknown), (unknown), Wei Lou, Alan P. Lombard, Chengfei Liu, Ai‐Ming Yu, Nicholas Mitsiades, Allen C. Gao	0
8	Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy 2024 ·Nature Communications ·Zhangyi Luo, Yixian Huang, Neelu Batra, Yuang Chen, Haozhe Huang, Yifei Wang, Ziqian Zhang, Shichen Li, Chien‐Yu Chen, Zehua Wang, Jingjing Sun, Qiming J. Wang, Da Yang, Binfeng Lu, James F. Conway, (unknown), Ai‐Ming Yu, Song Li	30
9	Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents 2024 ·RNA ·Gavin M. Traber, (unknown), Neelu Batra, Mei‐Juan Tu, Ai‐Ming Yu	6
10	Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment 2022 ·Molecular Cancer Therapeutics ·Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D’Abronzo, Neelu Batra, Ai‐Ming Yu, (unknown), (unknown), Christopher P. Evans, Allen C. Gao	16
11	Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy 2020 ·Molecular Cancer Therapeutics ·Maike Zimmermann, Tao Li, Thomas J. Semrad, Chun‐Yi Wu, Ai‐Ming Yu, George D. Cimino, Michael Malfatti, Kurt Haack, Kenneth W. Turteltaub, Chong‐Xian Pan, May Cho, Edward Kim, Paul T. Henderson	20
12	Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability 2020 ·Drug Metabolism and Disposition ·Joseph L. Jilek, Mei‐Juan Tu, Chao Zhang, Ai‐Ming Yu	19
13	A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells 2019 ·Cancer Research ·(unknown), Catalina Simion, (unknown), Neelu Batra, Anastasia L. Berg, Kermit L. Carraway, Ai‐Ming Yu, Colleen Sweeney	49
14	Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression 2018 ·Acta Pharmaceutica Sinica B ·(unknown), Ye Tian, Mei‐Juan Tu, Pui Yan Ho, Neelu Batra, Ai‐Ming Yu	56
15	Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models 2018 ·Cancer Letters ·Mei‐Juan Tu, Pui Yan Ho, (unknown), Chao Jian, (unknown), Edward Kim, Richard J. Bold, Frank J. Gonzalez, Huichang Bi, Ai‐Ming Yu	43
16	Metabolomics reveals mycoplasma contamination interferes with the metabolism of PANC-1 cells 2016 ·Analytical and Bioanalytical Chemistry ·Tao Yu, Yongtao Wang, Huizhen Zhang, Caroline H. Johnson, Yiming Jiang, Xiangjun Li, Zeming Wu, Tian Liu, Kristopher W. Krausz, Ai‐Ming Yu, Frank J. Gonzalez, Min Huang, Huichang Bi	15
17	ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development breakdown → 2014 ·Current Pharmaceutical Design ·Young Hee Choi, Ai‐Ming Yu	451
18	Potential Role of Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport 2013 ·Drug Metabolism and Disposition ·Magnus Ingelman‐Sundberg, Xiao‐bo Zhong, Oliver Hankinson, Sudheer Beedanagari, Ai‐Ming Yu, Lai Peng, Yoichi Osawa	54
19	In vivo Silk Fibroin Biocompatibility 2010 ·Investigative Ophthalmology & Visual Science ·Ana Paula Miranda Vieira, (unknown), Ai‐Ming Yu, (unknown), George J. Harocopos, Ivan R. Schwab	1
20	Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis 2005 ·Endocrinology ·Ai‐Ming Yu, Katsumi Fukamachi, Kristopher W. Krausz, Connie Cheung, Frank J. Gonzalez	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact